Anika Therapeutics (ANIK) closed out FY 2025 with Q4 revenue of US$30.6 million and basic EPS of US$0.13, alongside net income excluding extra items of US$1.8 million, providing a cleaner snapshot of its ongoing operations. Over recent quarters, the company reported revenue of US$26.2 million in Q1 2025, US$28.2 million in Q2, US$27.8 million in Q3, and US$30.6 million in Q4. EPS ranged from a loss of US$0.32 in Q2 to a profit of US$0.13 in Q4, giving investors a clearer view of how margins are shaping up behind the headline numbers.

See our full analysis for Anika Therapeutics.

With the latest figures on the table, the next step is to see how this revenue and EPS path lines up with the main narratives investors have been using to frame Anika Therapeutics, and where those stories might need to be reconsidered.

Losses Narrow On A Trailing Basis

• On a trailing 12 month view, Anika reported total revenue of US$112.8 million and a net loss excluding extra items of US$10.0 million, compared with quarterly net income excluding extra items that ranged from a loss of US$4.6 million in Q2 2025 to a profit of US$1.8 million in Q4 2025.
• Analysts' consensus view focuses on the trade off between modest revenue growth and an improving loss profile, and the latest numbers speak to that balance:
  • Revenue growth over the last year was 5.5% annually, while losses over the past five years have been reduced at an average rate of 13.3% per year. This is the core of the argument that the business is gradually moving toward a healthier earnings profile, even though the trailing 12 month period is still loss making.
  • At the same time, Q4 2025 net income excluding extra items of US$1.8 million contrasts with the trailing 12 month loss of US$10.0 million, so anyone leaning on the consensus narrative has to weigh a single profitable quarter against a full year that still shows negative earnings.

Revenue Growth Trails Market Benchmarks

• Revenue growth of 5.5% per year over the last 12 months sits below the 10.3% per year benchmark for the broader US market, while quarterly revenue in FY 2025 moved within a tight band from US$26.2 million in Q1 to US$30.6 million in Q4.
• For a bullish take that highlights product adoption in areas like Integrity and Hyalofast, this revenue profile creates a useful sense check:
  • Supporters point to rising demand for joint preservation and tendon repair solutions and the potential contribution from products such as Integrity and Hyalofast. Yet the 5.5% annual revenue growth rate and trailing 12 month revenue of US$112.8 million show that, so far, growth is present but not fast relative to the 10.3% market benchmark.
  • The consensus narrative also talks about future US approvals for Hyalofast and Cingal helping to offset pricing pressure in the OEM channel. This makes the current revenue level and the modest growth rate an important baseline for anyone expecting those future catalysts to shift the trajectory.

Bulls argue that the real story is how these joint preservation products could change the revenue mix over time, especially if approvals and adoption play out as expected. It can be helpful to compare that view against the current 5.5% growth rate and US$112.8 million trailing 12 month revenue before leaning too hard into the upside case. 🐂 Anika Therapeutics Bull Case

Valuation Screens As Relatively Low

• At a current share price of US$14.36, Anika trades on a P/S of 1.8x, compared with peer and US biotech averages of 17.9x and 12.6x respectively, and sits below an indicated DCF fair value of US$16.25.
• Critics highlight that the company is still loss making on a trailing 12 month basis and question how much weight to put on valuation alone:
  • The trailing 12 month net loss excluding extra items of US$10.0 million and Basic EPS of a loss of US$0.70 show that, even with Q4 2025 profitability, earnings are not yet positive over the full year, which matters for investors who prefer to see sustained profits rather than rely on low P/S ratios.
  • On the other hand, the 1.8x P/S and the gap between the US$14.36 share price and the US$16.25 DCF fair value mean the market is pricing Anika well below peers while the business still generated over US$112.8 million of revenue. Anyone taking a more cautious, quasi bearish stance needs to weigh that discount against the ongoing loss profile.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Anika Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of opportunities and risks feels finely balanced, it is worth checking the numbers yourself and moving quickly to form your own view. To see what the current optimism is built on, take a look at the 2 key rewards.

See What Else Is Out There

Revenue growth that trails the broader US market and a trailing 12 month loss of US$10.0 million indicate that earnings quality and momentum are still mixed.

If that combination of slower growth and ongoing losses makes you want stronger fundamentals, check out our solid balance sheet and fundamentals stocks screener (39 results) to find ideas backed by sturdier financial footing right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.